Asset Details
Do you wish to reserve the book?
RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis
Do you wish to request the book?
RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis
2019
Overview
Background
Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease characterized by upregulation of inflammatory cell death and osteoclastogenesis. Necrostatin (NST)-1s is a chemical inhibitor of receptor-interacting serine/threonine-protein kinase (RIPK)1, which plays a role in necroptosis.
Methods
We investigated whether NST-1s decreases inflammatory cell death and inflammatory responses in a mouse model of collagen-induced arthritis (CIA).
Results
NST-1s decreased the progression of CIA and the synovial expression of proinflammatory cytokines. Moreover, NST-1s treatment decreased the expression of necroptosis mediators such as RIPK1, RIPK3, and mixed lineage kinase domain-like (MLKL). In addition, NST-1s decreased osteoclastogenesis in vitro and in vivo. NST-1s downregulated T helper (Th)1 and Th17 cell expression, but promoted Th2 and regulatory T (Treg) cell expression in CIA mice.
Conclusions
These results suggest that NST-1s attenuates CIA progression via the inhibition of osteoclastogenesis and might be a potential therapeutic agent for RA therapy.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Ankle
/ Arthritis, Experimental - enzymology
/ Arthritis, Experimental - pathology
/ Arthritis, Rheumatoid - drug therapy
/ Arthritis, Rheumatoid - pathology
/ Biomedical and Life Sciences
/ Collagen
/ Disease
/ Imidazoles - therapeutic use
/ Immunobiology and immunotherapy
/ Inflammation Mediators - metabolism
/ Kinases
/ Male
/ Necrosis
/ Proteins
/ Receptor-Interacting Protein Serine-Threonine Kinases - antagonists & inhibitors
/ Receptor-Interacting Protein Serine-Threonine Kinases - metabolism
